Harvard Medical School, Boston, MA, USA.
Daiichi Sankyo, Basking Ridge, NJ, USA.
Leuk Lymphoma. 2023 Dec;64(13):2156-2164. doi: 10.1080/10428194.2023.2252123. Epub 2023 Sep 15.
Outcomes for chronic myelomonocytic leukemia (CMML) are insufficiently characterized at the population level. We analyzed epidemiological trends for patients between 2001 and 2017, focusing on age, sex, race, and long-term survivors. Using the Surveillance, Epidemiology, and End Results Program, we studied 3929 patients, in four time-period (tp) cohorts, based on year of diagnosis [2001-2004 (tp1); 2005-2009 (tp2); 2010-2013 (tp3); 2014-2017 (tp4)]. Stable incidence overall, male predominance, and higher incidence for White versus Black and 'Other' races were noted. Three-year relative survival (RS) increased from 27.9% to 36.9% between tp1 and tp4. The most pronounced increase occurred between tp1 and tp2. All subgroups generally experienced RS improvements over time, except notably Black patients. Improvements for patients aged 85+ (3-year RS 8.4-23.6% between tp1 and tp4) and increases in long-term survivors (5-year OS from 13.2-22.3%) were observed. Additional study is warranted to explore these associations, particularly for Black patients.
慢性髓单核细胞白血病（CMML）的人群水平结局特征不足。我们分析了 2001 年至 2017 年间患者的流行病学趋势，重点关注年龄、性别、种族和长期幸存者。我们使用监测、流行病学和最终结果计划（SEER），根据诊断年份（2001-2004 年[tp1]；2005-2009 年[tp2]；2010-2013 年[tp3]；2014-2017 年[tp4]）研究了 3929 名患者，分为四个时间队列（tp）。我们观察到总体发病情况稳定、男性居多，以及白种人发病率高于黑人和“其他”种族。3 年相对生存率（RS）从 tp1 到 tp4 从 27.9%增加到 36.9%。最大的增长发生在 tp1 和 tp2 之间。所有亚组的 RS 总体上随时间改善，除了黑人群体外。观察到 85 岁以上患者（tp1 至 tp4 之间的 3 年 RS 为 8.4-23.6%）和长期幸存者（5 年 OS 从 13.2-22.3%）的改善。需要进一步研究来探讨这些关联，特别是针对黑人群体。
